^
    19h
    A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, BeOne Medicines
    New P3 trial
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    1d
    Harnessing Venetoclax in NPM1-Mutated AML: A Path to Sustained Remission and Beyond. (PubMed, Cancers (Basel))
    Venetoclax-based regimens represent a major advancement in the treatment of NPM1-mutated AML, promoting a shift toward more targeted and less toxic therapeutic approaches. Nonetheless, prospective randomized trials are required to establish standardized clinical algorithms and to refine maintenance and discontinuation strategies, with the ultimate goal of improving patient quality of life and long-term outcomes.
    Review • Journal • IO biomarker
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    |
    Venclexta (venetoclax)
    1d
    Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Onureg (azacitidine oral)
    1d
    VALOR: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets (clinicaltrials.gov)
    P=N/A, N=120, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Real-world evidence
    |
    Venclexta (venetoclax)
    1d
    Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=53, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)
    2d
    Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group. (PubMed, PeerJ)
    Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).
    Clinical data • Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    TP53 mutation • FLT3 mutation • NPM1 mutation • KIT mutation • TET2 mutation
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • idarubicin hydrochloride
    2d
    A case report of mixed-phenotype acute leukemia with atypical BCR::ABL1 e13a3 fusion gene. (PubMed, Medicine (Baltimore))
    At present, there is no established consensus on the treatment of Ph + MPAL, and reports on cases with the atypical e13a3 BCR::ABL1 fusion are particularly scarce. This finding will bring new insights and references for the diagnosis and treatment of Ph + MPAL.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 fusion
    |
    Venclexta (venetoclax) • dasatinib • bortezomib • cyclophosphamide
    3d
    Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. (PubMed, Trials)
    This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML.
    Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1)
    |
    TP53 mutation • FLT3-ITD mutation
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    3d
    A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    3d
    CRTC2 Promotes AML Progression and Mediates Mitochondrially-Driven Venetoclax Resistance. (PubMed, FASEB J)
    Inhibiting CRTC2 reduces mitochondrial translation and energy reserves, increasing AML cell sensitivity to VEN. These results highlight CRTC2 as a promising therapeutic target and suggest a new strategy to overcome VEN resistance.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    Venclexta (venetoclax)
    4d
    ASCERTAIN-V: Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=101, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
    4d
    22P.205: Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Thomas Jefferson University | Phase classification: P1/2 --> P1
    Phase classification
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)